Loading organizations...
§ Private Profile · 817 W Peachtree St NW, Atlanta, Georgia 30308, US
Biotechnology company developing proprietary off-the-shelf g-NK cell therapies for blood cancers, solid tumors, and autoimmune diseases.
Key people at Idapta.
Idapta Therapeutics, based in San Francisco, California, develops a proprietary platform utilizing naturally occurring g-NK (FcRγ-deficient natural killer) cells to create off-the-shelf cell therapies for blood cancers, solid tumors, and autoimmune diseases. The company has raised over $72.5 million, including a Series A round exceeding $50 million in 2022 and an additional $22.5 million in December 2024. Investors include RA Capital Management, Leaps by Bayer, and Vertex Ventures HC; Mark Frohlich was appointed CEO in 2022. The company's therapies often combine with monoclonal antibodies, advancing cancer treatments from UH Tech Bridge since 2020 and securing funding for its IDP-023 g-NK therapy. Idapta Therapeutics was founded in 2017 by Guy DiPierro, Ronald Martell, Sungjin Kim, and John Sunwoo.
Key people at Idapta.
Indapta Therapeutics is a clinical-stage biotechnology company developing off-the-shelf, allogeneic natural killer (NK) cell therapies using its proprietary platform of FcRγ-deficient g-NK cells derived from healthy donors. These therapies target blood and solid-tumor cancers, as well as autoimmune diseases, by harnessing potent immune cells that kill cancer cells and autoreactive T/B cells, either alone or combined with FDA-approved antibodies like rituximab and daratumumab[1][3][4]. The company serves patients with unmet needs in oncology and autoimmunity, addressing limitations of current therapies through scalable, accessible treatments; it recently raised $22.5 million in December 2024 from investors including Leaps by Bayer, RA Capital Management, Pontifax, Vertex Ventures, and Myeloma Investment Fund to advance clinical trials for lead candidate IDP-023, showing promising preclinical superiority over conventional NK cells[1][4][5].
Headquartered in Houston, TX, and Seattle, WA, Indapta demonstrates strong growth momentum with ongoing Phase 1 trials in cancer, a planned Q1 2025 trial in multiple sclerosis, and a collaboration with Sanofi, building on prior funding exceeding $100 million[3][4][6].
Indapta Therapeutics emerged from research into a rare subset of naturally occurring NK cells lacking the FcRγ protein (g-NK cells), identified for their superior potency against cancer and autoimmune targets. The company, privately held and clinical-stage, is advancing this discovery into therapies like IDP-023, with pivotal preclinical demonstrations of robust anti-cancer effects in models of non-Hodgkin lymphoma (with rituximab) and multiple myeloma (with daratumumab)[3][4]. Key early traction includes securing high-profile investors and closing a $22.5 million round on December 17, 2024, from repeat backers like RA Capital and Leaps by Bayer, alongside a Sanofi collaboration, enabling acceleration toward human data readout[1][4]. Leadership under CEO Mark Frohlich has driven this momentum, with the funding earmarked for expanding trial data in cancer and initiating autoimmune studies[4].
(Note: Specific founder names and exact founding year are not detailed in available sources, though the company's evolution centers on its g-NK platform from discovery to clinic[3].)
Indapta stands out in the cell therapy field through these key strengths:
Indapta rides the surging wave of allogeneic cell therapies, a trend shifting from personalized autologous treatments (e.g., CAR-T) toward scalable, off-the-shelf NK cell platforms amid demand for faster, cheaper cancer and autoimmune solutions. Timing is ideal post-2024 funding boom, with market forces like rising autoimmune prevalence, antibody combination successes, and Big Pharma interest (e.g., Sanofi deal) favoring potent NK innovations over riskier autologous rivals[3][4]. In biotech's ecosystem, Indapta influences by pioneering g-NK cells—rarer, hyper-potent variants—potentially expanding NK therapy adoption beyond early leaders, while investor backing from Bayer and RA Capital signals validation for next-gen immuno-oncology[1][4].
Indapta is poised for inflection with near-term Phase 1 data from IDP-023 in cancer and MS trial launch, potentially de-risking its g-NK platform for partnerships or further raises amid NK cell therapy's maturation. Trends like antibody synergies, autoimmune expansion, and manufacturing advances will propel growth, evolving Indapta from preclinical promise to a scalable leader in accessible cell therapies—echoing its mission to harness nature's immune power for unmet needs[3][4].
